Home
 /
Papers
 /
Neuroscience
 /
Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease
Preprint
Open access
V1
Top 1% · Validated by QED

Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease

Daisy Yi Ding, Veronica Augustina Bot, Kenneth L Chen +12 more
February 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.02.10.704909
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Neuroscience this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

This study overturns organism-centric aging models by resolving biological age across 40+ distinct cell types using plasma proteomics alone, demonstrating that heterogeneous cellular aging trajectories—not chronological age—dictate disease susceptibility and mortality.

QED claims analysis

Summary

Plasma proteomic profiling of over 7,000 proteins across 60,000 individuals reveals that biological aging occurs heterogeneously across more than 40 distinct cell types, with cell type-specific aging signatures predicting incident neurodegenerative disease, cancer, chronic disease, and mortality years before clinical onset, while extreme astrocyte aging confers Alzheimer's disease risk comparable to APOE4 carrier status and youthful immune or neuronal profiles provide protective effects against mortality.

See full analysis
Main Claim 1 –

Plasma Proteomics Enables Machine-Learned Cell Type Aging Clocks

Supporting evidence

  • Plasma Protein Trajectories Cluster by Cell Types and Pathways
Main Claim 2 –

Humans Show Heterogeneous, Cell Type-Specific Accelerated Aging

Supporting evidence

  • APOE Genotype Antagonistically Affects Astrocyte Versus Macrophage Aging
Main Claim 3 –

Neurodegenerative Diseases Show Distinct Cellular Aging Signatures

Supporting evidence

  • Astrocyte Aging Correlates with pTau-217 and Cognitive Decline
Main Claim 4 –

Extreme Skeletal Myocyte and Astrocyte Aging Predict ALS and AD

Supporting evidence

  • Astrocyte Aging Synergizes with APOE4 to Increase AD Risk

Abstract

Aging is asynchronous across cells and organs, but whether plasma proteins can capture cell type-specific aging and predict disease and mortality remains unknown. We developed machine learning models to estimate the biological age of more than 40 distinct cell types—spanning neuronal, immune, glial, endocrine, epithelial, and musculoskeletal origins—using over 7,000 plasma proteins measured in 60,000 individuals across three cohorts, comprising the largest human plasma proteomics aging study to date. Individuals showed heterogeneous aging profiles, with 20-25% exhibiting accelerated aging in a single cell type and 1-3% across ten or more cell types. APOE genotype showed antagonistic aging effects in different cell types: APOE4 carriers exhibited older astrocytes but younger macrophages, while APOE2 carriers showed the inverse. Cellular aging signatures were uniquely associated with disease status and predicted incident disease and mortality over 15 years of follow-up. Amyotrophic lateral sclerosis (ALS) showed the strongest association with skeletal myocyte aging (hazard ratio = 12.7 for extreme accelerated versus youthful aging). In Alzheimer’s disease (AD), prevalent cases showed accelerated aging across multiple neural and peripheral cell types, with extreme astrocyte aging conferring AD risk comparable to APOE4 carrier status. Moreover, extreme astrocyte aging increased AD risk in APOE4/4 carriers threefold, while youthful astrocytes strikingly reduced risk. Beyond neurodegeneration, respiratory cell aging identified smokers at 58% higher lung cancer risk, and myeloid aging identified normoglycemic individuals at higher diabetes risk. Both specific cellular vulnerabilities and cumulative aging burden influenced survival, wherein youthful immune or neuronal profiles were protective. A polycellular aging risk score provided robust mortality risk stratification across platforms and cohorts. These findings establish a framework for quantifying biological aging at the cellular resolution using plasma proteomics, revealing heterogeneity in aging trajectories and their impact on disease susceptibility and resilience.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?